>>
Industry>>
Healthcare>>
Aurobindo Pharma Voluntarily R...Aurobindo Pharma Voluntarily Recalled Mirtazapine Tablets On The U.S. Market.
The Silicon Review
21 January, 2020
Author:
The Silicon Review Team
Aurobindo Pharma USA Inc said Mirtazapine tablets, used for the treatment of the major depressive disorder, are voluntarily recalled on the U.S. market. Due to a label error on reported power, the drug is being recalled. Bottles labeled as Mirtazapine 7.5 mg may contain 15 mg tablets, as announced on the United States Food and Drug Administration (USFDA) website by the company. The company is reminding consumer-level lot number03119002A3 of tablets, it added. Ingesting high dose of the drug can lead to the risk of sedation, restlessness, increased reflexes, tremor, and more.
Unexpected levels OR high-levels of sedation can contribute to falls in older people or motor vehicle accidents. The company notifies its customers by mail and arranges for the return of the product that is recalled. Distributors/retailers with a recalled product will refund the bottle(s) to the place of purchase. Users can recognize the product by checking the name of the drug, the description of the manufacturer, and the batch or lot number on the container. Patients or consumers can contact their physician or healthcare provider if they have encountered any problems that may be linked to taking or using this drug.
